PeptiGrowth Inc., based in Chiyoda-ku, Tokyo, has unveiled an innovative synthetic peptide known as the "FGF2 alternative peptide (FGFR1c agonist)," designed to mimic the functionalities of recombinant Fibroblast Growth Factor 2 (FGF2). The launch of this product, set for early October 2024, marks a significant advancement in regenerative medicine and therapeutic applications, especially in wound healing and tissue repair.
FGF2 plays a pivotal role in various biological processes, including